ABBOTT PARK, Ill., Nov. 6, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) today announced results from long-term open-label extensions of the PREMIER and DE019 Phase 3 studies, which evaluated HUMIRA® ...
Dear Dr. Roach: I’m a 67-year-old healthy male, but I do take Humira for rheumatoid arthritis (RA). It does a wonderful job for me with no side effects. It does such a good job that I can periodically ...
Jan. 2, 2003 — Abbott Laboratories received U.S. Food and Drug Administration (FDA) approval this week to market adalimumab (Humira), previously known as D2E7. The drug was approved for the treatment ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback